





Mother's Identification Code :	Neonate's Identification Code:

#### **Introduction**

This standardized Case Report Form (CRF) is the result of an ongoing effort between the World Health Organization (WHO), The Pan-American Health Organization (PAHO), Institute Pasteur (IP), and the networks of ISARIC, CONSISE PREPARE and REACTing to generate standardized clinical and epidemiological research tools.

#### **DESIGN OF THIS CASE REPORT FORM (CRF)**

There are two sets of Case Report Form (CRF) to be used - Neonate and Maternal. The CRFs are to be used in combination for prospective cohort studies or case control studies.

These sets of CRFs are to be used at admission and at discharge/going home. For any patients admitted for more than 24 hours, the Baseline and Outcome CRF and the Laboratory Results CRF can be copied and used for daily data recording.

For all studies, we recommend completing a minimum of the Maternal Baseline and Outcome (MBO) and Neonate Baseline and Outcome (NBO) CRFs, follow by Maternal Laboratory Results (MLR) and Neonate Laboratory Results (NLR) CRFs for all neonates post-delivery. If the mother and/or neonate is admitted to an Intensive Care Unit or Pediatric Intensive Care Unit, complete Maternal Intensive Care (MIC), and/or Neonate Intensive Care (NIC) as well.

For pregnant women presenting with acute symptoms, complete **Maternal Acute Symptoms (MAS)**, and for all studies complete **Maternal Antenatal Care (MAC)**.

Complete the outcomes sections in CRFs MBO and NBO once all diagnostics laboratory results and final diagnosis are available.

#### **HOW TO USE THIS CRF**

When completing the CRF modules, please make sure that:

- The mother or consultee/guardian/representative has been given information about the study and the informed consent form has been completed and signed.
- The study ID codes have been assigned for both mother/pregnant woman and neonate as per hospital protocol and guidelines.
- The study ID codes should be filled in on all pages of paper CRF forms, all information should be kept confidential at all times, and no identifiable information is recorded on the CRFs.
- Patients' hospital ID and contact details are recorded on a separate contact list to allow later follow up. The contact forms must be kept separate from the CRFs at all times and kept in a secure location.

Each site may choose which data to collect based on available resources and the number of patients enrolled to date. Ideally, data on patients (neonate and mother) will be collected using all CRF modules as appropriate.

Sites with very low resources or very high patient numbers may select Maternal and Neonatal Baseline and Outcome CRF modules. The decision is up to the Site Investigators and may be changed throughout the data collection period. All high quality data is valuable for analysis.

#### **GENERAL GUIDANCE**

- The CRFs are designed to collect data obtained through patient examination, through parent/guardian/representative (for neonates) interview and review of hospital notes.
- Patient ID codes should be filled in on all pages of paper CRF forms (neonate and mother).
- Complete every line of every section, except for where the instructions say to skip a section based on certain responses.
- Selections with square boxes ( ) are single selection answers (choose one answer only). Selections with circles ( ) are multiple selection answers (choose as many answers as are applicable).
- It is important to indicate when the answer to a particular question is not known. Please mark the 'Unknown' box if this is the case
- Some sections have open areas where you can write additional information. To permit standardized data entry, please avoid writing additional information outside of these areas.
- We recommend writing clearly in black or blue ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) when you choose the corresponding answer. To make corrections, strike through (----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please keep all of the sheets for each study subject together e.g. with a staple or in a folder that is unique to the patient.







	,
Mother's Identification Code :	Neonate's Identification Code :

· Please contact us if we can help with any CRF completion questions, if you have comments and to let us know that you are using the forms. Please contact Dr Gail Carson by email: <a href="mailto:gail.carson@ndm.ox.ac.uk">gail.carson@ndm.ox.ac.uk</a>

Disclaimer: These CRFs are intended for use as a standardized document for the collection of clinical data in studies investigating the Zika virus. Responsibility for use of these CRFs rests with the study investigators. ISARIC and the authors of the CRF accept no responsibility for the use of the CRF in an amended format nor for the use of the standardized CRF outside its intended purpose. Formatting issues are in the process of being resolved. Word documents are available in order to adapt and translate the CRFs, however, there may be issues between Macs and PCs. The PDF format is also available, which should be well formatted on both systems.

NCLUSION CRITERIA Define as appropriate for each stu	dy and as	per latest na	ational g	uidelines.		
CONCENT						
CONSENT nsure informed consent.						
insure informed consent.						
Date and time of consent (dd/m	m/yyyy):	/	_/_20_	Time	e::(l	nours:min)
Name and role of the person tal		ent :				
Signature of person taking cons	ent:					
1. Name of site/clinic/hospital						
2. Geoposition	Latin	tude			Longitude	•
<u> </u>						
If geoposition not available, state		n below				
Name of the site/clinic/hospital						
3. City/town /village:						
4. Country (& region/district):						
The Country (a region) districts.						
5. Acute symptoms in pregnant	□Ye	es 🗆 No				
mother	If ye	If yes, please also complete the Maternal Acute Symptoms CRF				
) MATERNAL DEMOGRAPI	HICS					
6. Date of birth (dd/mm/yyyy)	/	/				
7. Ethnicity (according to			_			
national guidelines):						
8. Home city/town /village duri	ng pregna	ncy, state al	l during	this pregna	incy	
City/town/village			Date fi	rom (mm/y	ууу)	To (mm/yyyy)
9. Occupation						
10. Height				□cm □	feet/inches	
11. Weight (prior to		□kg		12. Curre		□kg
pregnancy, specify or		□pounds/	ounces		<b>5</b> -	□pounds/ounces
estimate):		рошіаз/				pounds/ounces
13. Familial genetic conditions	□Yes			If yes, spe	ecify:	
on maternal or paternal side	□No					
	□Unkno	own				



**Mother's Identification Code:** 

## ZIKA VIRUS CASE REPORT FORMS – MATERNAL BASELINE AND OUTCOME – (MBO)

**Neonate's Identification Code:** 





<b>14. Number of previous pregnancies</b> (excluding present pregnancy):					ber of previous ter 22 weeks' n:	
16. Have any previous babies been (tick all that apply)		m (<37 wee rn or perina Unknov	atal death	· ·		
17. Have any previous babies weighed (tick all that apply):	0 < 2.5 k □No	kg ○>4.5kg □Unkno			e any previous nad microcephaly	□Yes □No □ Unknown
19. Have any previous babies had other congenital abnormalities	□Yes □No □Unkno	own		If yes, sp	oecify:	
20. Consanguinity	□Yes	□No□	]Unknowr	1		
21. If not yet delivered, what is the current gestational age	Weeks	Days		mated da	vered, what is te of delivery	//20
23. Estimated date of conception (dd/mm/yyyy)	/_	/ 20 _				
24. Birth number	□Single	eton $\Box Tw$	in □Trip	let □Oth	er, please detail:	
25. National or international travel during this pregnancy	□Yes □No □Unkno	own				
If yes, specify all countries or reg	gions visit	ed below				
Country/region visited	Appr	oximate fir	st and las	t date	Duration of visit	Includes overnight
		(dd/mn	n/yyyy)		(days)	stay
	/	/ to	/_	/		☐ Yes ☐ No
	/	/ to	/_	/		☐ Yes ☐ No
	/	/ to	/_	./		☐ Yes ☐ No
	/_	to	/_	./		☐ Yes ☐ No
		/ to		/		☐ Yes ☐ No
ote: If further demographic or epidemiology information is required please use a complementary ZIKV CRF emographics and Epidemiology  MATERNAL CHRONIC COMORBIDITIES / PAST MEDICAL HISTORY						
26. Chronic cardiovascular disea	se <sup>1</sup>				□Yes □No	Unknown
27. Chronic pulmonary disease <sup>2</sup>						Unknown
28. Blood disorders					□Yes □No	□Unknown

<sup>&</sup>lt;sup>1</sup> Includes coronary heart disease, cerebrovascular disease (stroke), hypertension (Diastolic > 100), peripheral artery disease, rheumatic heart disease, congenital heart disease and heart failure. www.who.int/topics/cardiovascular\_diseases/en/

<sup>&</sup>lt;sup>2</sup> Chronic lung diseases that cause limitations in lung airflow (previously referred to as emphysema, chronic bronchitis), diagnosed by spirometry or clinical signs e.g. abnormal shortness of breath and increased forced expiratory time. www.who.int/respiratory/copd/diagnosis/en/







nother's identification code:	Neonate's identification co	ue	
If yes, specify:			
29. Chronic renal/kidney disease <sup>3</sup>		□Yes □No □Unknown	
30. Chronic liver disease – moderate or sev	ere <sup>4</sup>	☐Yes ☐No ☐Unknown	
31. Chronic neurological disease <sup>5</sup>		□Yes □No □Unknown	
If yes, specify:			
<b>32. Paralysis</b> (existing prior to this pregnance	y)	□Yes □No □Unknown	
If yes, specify body parts affected:			
33. Type 1 Diabetes		☐Yes ☐No ☐Unknown	
34. Type 2 Diabetes and treated with oral n	nedicine or insulin dependent	□Yes □No □Unknown	
35. Other endocrine disease <sup>6</sup>		□Yes □No □Unknown	
If yes, specify:			
36. Rheumatologic disease <sup>7</sup>		☐Yes ☐No ☐Unknown	
37. Immunosuppression		☐Yes ☐No ☐Unknown	
38. HIV <sup>8</sup>		□Yes □No □Unknown	
If yes, on antiretroviral therapy?		□Yes □No □Unknown	
39. CD4 cell count		□ <200 cells/μL □ 200-499 cells/μL	
		□ ≥500 cells/μL □ Unknown	
40. Other immunosuppression?		☐Yes ☐No ☐Unknown	
If yes, specify:			
41. Any other chronic comorbidity		□Yes □No □Unknown	
If yes, specify:			
) MEDICATIONS DURING THIS PREC	<b>GNANCY</b> (prior to onset of curr	ent illness episode)	
42. Fever or pain treatment	Acetaminophen/paracetamo	I □Yes □No □Unknown	
	NSAID/s	□Yes □No □Unknown	
	Other/s (specify):		
43. Anticonvulsants	☐Yes ☐No ☐Unknown If yes, specify generic name:		
44. Drug against nausea during this pregnancy	☐Yes ☐No ☐Unknown If y	res, specify generic name:	
45. Prenatal vitamins	☐Yes ☐No ☐Unknown If y	res, specify (e.g. folic acid):	

# 4) OTHER MEDICATIONS USED DURING THIS PREGNANCY

 $<sup>^{3}</sup>$  Creatinine >3mg% (265  $\mu mol/l)\text{, dialysis, transplantation, uremic syndrome}$ 

<sup>4</sup> Cirrhosis with PHT +/- variceal bleeding

<sup>5</sup> Disorders of the nervous system e.g. epilepsy, MS, Parkinson, chronic pain syndromes, chronic brain injuries, ALS etc.

<sup>6</sup> Hypopituitarism, adrenal insufficiency, recurrent acidosis

<sup>7</sup> SLE, polymyositis, polymyalgia rheumatic, mixed connective tissue diseases

<sup>8</sup> Laboratory-confirmed HIV-1 or HIV-2 infection (irrespective of the CD4 lymphocyte count/percentage or HIV viral load in blood), or a patient with an AIDS-defining condition.







Mother's Identification Code	:	Neonate's Ident	tification Co	ode :
-	als and other re	-	•	during this pregnancy episode, oal, and non-licensed remedies. Please
Medications or herbal rem	edies or others	including non-	Route of	administration
licensed				
			☐ Oral ☐	] IV □ Rectal □ Topical □Other:
			☐ Oral ☐	] IV □ Rectal □ Topical □ Other:
			☐ Oral ☐	] IV ☐ Rectal ☐ Topical ☐ Other:
			☐ Oral ☐	] IV ☐ Rectal ☐ Topical ☐ Other:
			☐ Oral ☐	IV ☐ Rectal ☐ Topical ☐ Other:
			☐ Oral ☐	IV □ Rectal □ Topical □Other:
			☐ Oral ☐	IV □ Rectal □ Topical □Other:
5) SMOKING, ALCOHOL	., DRUGS AN	ID BLOOD TRANSI	FUSION -	- RISK FACTORS
47. Smoking during this	□Yes	If yes, specify averag	e per	☐ Other forms of smoking/tobacco
pregnancy	□No	day:		Specify:
	□Unknown	□ <10 cigarettes per □ ≥10 cigarettes per	•	
48. Alcohol consumption	□Yes	If yes, specify averag	e alcohol	Specify type:
during this pregnancy	□No	consumption per day		Specify type.
during this pregnancy		Less than 1-2 alcol		
	□Unknown	drinks <sup>9</sup> per day	IIOIIC	
		· · ·		
		2-5 alcoholic drink		
		□ >5 alcoholic drinks	· · · · · ·	
49. Illicit and	□Yes	If yes, specify freque	-	Specify all types of drugs used and
recreational drug use	□No	$\square$ 0-1 occasion per w		route of administration:
during this pregnancy	□Unknown	2-5 occasions per		Type:
		☐ >5 occasions per v	veek	
				Route:
50. Has the patient	□Yes	Specify/estimate dat	e of last	Reason for transfusion:
received a blood	□No	blood transfusion		
transfusion?	□Unknown	□< 30 days ago		
		□>30 days ago		

Note: If further demographic or epidemiology information is required please use the complementary ZIKV CRF Demographics and Epidemiology

 $<sup>^9</sup>$  A drink is defined as any alcoholic drink for example a glass of wine, a glass of beer, a cocktail ZIKV CRF Maternal Baseline and Outcome v6.1 05DEC2016







ISARIC	BASELINE AND OUTCOME – (MBO)	REACTing	Ellhandi on Italiana
Mother's Identification Code:	Neonate's Identification Code :		

#### 6) MATERNAL IMMUNISATION HISTORY

Vaccine	Immunized	Date of last dose (dd/mm/yyyy)
51. Rubella	□Yes □No □Unknown	
52. Measles	□Yes □No □Unknown	
53. Mumps	□Yes □No □Unknown	
54. Acellular pertussis	☐Yes ☐No ☐Unknown	
55. Varicella	□Yes □No □Unknown	
56. Tetanus	□Yes □No □Unknown	
57. Diphtheria	□Yes □No □Unknown	
58. Polio	□Yes □No □Unknown	
59. Seasonal influenza	□Yes □No □Unknown	
60. Yellow fever	□Yes □No □Unknown	
61. Japanese encephalitis	□Yes □No □Unknown	
62. Tick-borne encephalitis	□Yes □No □Unknown	
63. Dengue virus	□Yes □No □Unknown	
64. Hepatitis B	☐Yes ☐No ☐Unknown	
65. Any other vaccinations received	□Yes □No □Unknown	
during this pregnancy	If yes, please specify	
	immunization type:	
Any other vaccinations received during	□Yes □No □Unknown	
this pregnancy	If yes, please specify	
	immunization type:	

**7) DIAGNOSTIC OUTCOME MOTHER** Record final diagnostics outcomes based on laboratory results, clinical picture, and case definitions. Choose the appropriate case definition, e.g. WHO or national/local case definition and ensure the definition used is clear and shared with all involved in the study.

Pathogen	Diagnosis	Date of onset	Comment
		(dd/mm/yyyy)	
66. No confirmed diagnosis	☐ Tick if no diagnosis made		
67. Zika virus	☐ Confirmed acute infection		
	☐Probable acute infection		
	☐Confirmed past infection	_/_/	
	☐Probable past infection		
	☐Negative ☐Not tested		
	□Unknown		
68. Dengue virus	☐ Confirmed acute infection		
	☐Probable acute infection		
	☐Confirmed past infection	_/_/	
	☐Probable past infection		
	☐Negative ☐Not tested		
	□Unknown		
69. Yellow fever virus	☐ Confirmed acute infection		
	☐Probable acute infection		
	☐Confirmed past infection	//	







Mother's Identification Code :	Neonate's Identific	cation Code :	
	☐Probable past infection		
	☐Negative ☐Not tested		
	□Unknown		
70. West Nile virus	☐ Confirmed acute infection		
	☐Probable acute infection		
	☐Confirmed past infection	//	
	☐Probable past infection		
	□Negative □Not tested		
	□Unknown		
71. Chikungunya virus	☐ Confirmed acute infection		
7 In China angunya tinas	□ Probable acute infection		
	☐Confirmed past infection	/ /	
	☐Probable past infection		
	□ Negative □ Not tested		
	Unknown		
72. Toxoplasmosis	☐ Confirmed acute infection		
72. 1000pia3i1103i3	□ Probable acute infection		
	☐ Confirmed past infection	_/_/	
	□ Probable past infection		
	•		
	□ Negative □ Not tested □ Unknown		
73. Rubella	☐ Confirmed acute infection		
75. Rubella			
	☐ Probable acute infection	, ,	
	☐Confirmed past infection		
	☐ Probable past infection		
	□ Negative □ Not tested		
74.6.1	Unknown		
74. Cytomegalovirus	☐ Confirmed acute infection		
	☐Probable acute infection	, ,	
	☐Confirmed past infection		
	☐Probable past infection		
	□ Negative □ Not tested		
	Unknown		
75. Herpes Simplex Virus	☐ Confirmed acute infection		
	☐Probable acute infection	, ,	
	☐Confirmed past infection	_/_/	
	☐Probable past infection		
	☐ Negative ☐ Not tested		
	□Unknown		
76. Syphilis	☐ Confirmed acute infection		
	☐Probable acute infection	, ,	
	☐Confirmed past infection	_/_/	
	☐Probable past infection		
	☐Negative ☐Not tested		
	□Unknown		
77. Other (specify):	☐ Confirmed acute infection		
	☐Probable acute infection		







nother sidentification code:		ate s identini	cation code .	
	☐Confirmed past inf	ection	_/_/	
	☐Probable past infe	ction		
	□Negative	·		
Other (specify):	☐ Confirmed acute i	nfection		
	☐Probable acute inf	ection		
	☐Confirmed past inf		//	
	☐Probable past infe			
	□Negative			
			<u>l</u>	
S) FINAL OUTCOME				
Outcome		Details		
78. Date of discharge/going	home (dd/mm/yyyy)			
		//20		
79. Maternal outcome at dis	scharge/going home	□Discharge	ed/sent home without	sequelae Discharged
		with sequel	ae □Deceased □U	nknown
If discharged/ sent home w	ith sequelae, describe:			
80. If deceased, specify date	e of death (dd/mm/yyyy)	//2	0	
81. Birth outcome		☐Live birth		
		□Antepart	um death □Intra	partum death
		□Spontane	eous abortion	apeutic abortion
82. Maternal Zika virus infe	ction	□Positive	□Probable □Neg	ative
		□Unknowr	n □Not tested	
83. Diagnosis confirmed by		□Lab. conf	irmed local hospital la	aboratory
			irmed by national refe	
		□Lab. conf	irmed by internationa	I reference laboratory
		□Other, please detail:		
84. Other maternal outcome	es, specify all:			
) CASE REPORT COMPL	ETED BY			
Name and role				
Signature	Signature			// 20
<u> </u>				I